Community/Retail

In a session at the American Pharmacists Association Annual Meeting, Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPS-AQ Cardiology, CACP, provided practical insights for pharmacists to optimize the care of patients with cardio-kidney-metabolic conditions.

The FDA removed the age requirement from the neffy 1-mg label, allowing use based solely on weight and expanding access to younger pediatric patients at risk for anaphylaxis.

CDC flags a late respiratory syncytial virus (RSV) rise, while the NFID urges spring vigilance, vaccines, and monoclonals to protect infants and older adults from this virus.

Joseph Saseen, PharmD, explains the 2026 dyslipidemia guidelines' push for universal lipoprotein A screening, clarifies when apolipoprotein B testing adds value, and outlines how new FDA-approved therapies fit into the updated lipid-lowering treatment algorithm.

Volunteer service strengthens pharmacists’ empathy, confidence, and communication, boosting patient trust, teamwork, and community connection.

Insulin icodec-abae injection becomes the first and only once-weekly basal insulin option, offering personalized care for adults with type 2 diabetes (T2D).

Jacinda “JAM" Abdul-Mutakabbir, PharmD, MPH, discusses the adult burden of respiratory syncytial virus (RSV) and the critical role of pharmacists in vaccine access and education—especially for marginalized populations.

A panel of neurology pharmacy specialists discusses the expanding clinical role of pharmacists in multiple sclerosis care.

The FDA ramps up action on compounded GLP‑1 weight‑loss drugs, targeting telehealth ads as Novo Nordisk sues Hims & Hers and regulators hint at seizures.

Craig Beavers urges pharmacists to engage with obstructive hypertrophic cardiomyopathy (oHCM) management and explains how the alignment between mavacamten's clinical trial data and real-world outcomes validates its role as a safe, effective, and sustainable long-term therapy.

Independent pharmacies produce some of health care’s most valuable data, yet much of the profit and power they create bypasses the pharmacies entirely.

A new 2026 American Heart Association study shows COVID-19 infection sharply raises heart attack risk, whereas vaccination appears safe—key guidance for patient counseling.

Ahead of the Sports Pharmacy Summit, a pharmacist weighs GLP-1s for athlete weight management benefits.

Long-acting HIV injections and twice-yearly PrEP reshape care, while pharmacists tackle stigma, insurance hurdles, and adherence to close access gaps.

Clinical pharmacists reshape PBMs with medication optimization, cutting drug spend and improving outcomes through smarter, safer prescribing.

Swapping 30 minutes of teen sedentary time for vigorous activity or extra sleep cuts insulin resistance by 15%, aiding type 2 diabetes (T2D) prevention.

Joseph Saseen, PharmD, breaks down how the new PREVENT ASCVD calculator improves on its predecessor and what the expanded LDL-C goal framework means for treatment decisions in pharmacy practice.

Deucravacitinib, a selective TYK2 inhibitor, demonstrates efficacy comparable to biologics while offering meaningful improvements in symptoms and quality of life for patients with psoriatic arthritis.

Craig Beavers discusses how mavacamten's established long-term safety data strengthen shared decision-making conversations, and outlines best practices for multidisciplinary collaboration when implementing cardiac myosin inhibitor therapy in patients with obstructive hypertrophic cardiomyopathy (oHCM).

Emerging therapies, AI, and patient-centered approaches are reshaping cardiovascular pharmacy.

Nutrition coaching and pharmacist support boost medication adherence, tackle access barriers, and strengthen chronic disease routines.

Craig Beavers explains how mavacamten's REMS program and its clearly defined echo-based monitoring protocols create a unique opportunity for pharmacists to take an active role in managing patients with obstructive hypertrophic cardiomyopathy (oHCM).

This week's episode covers the court ruling halting RFK Jr.'s childhood vaccine schedule changes, the FDA's RSV vaccine approval for adults aged 18–49, pharmacist-led GLP-1 optimization strategies, and new gabapentin data in SUD treatment settings.

Sharon Nachman, MD, equips pharmacists with clear, evidence-based talking points to address vaccine hesitancy and help parents navigate the confusion created by the legal battle over childhood immunization schedules.

Community pharmacists boost asthma control by improving adherence, inhaler technique, and access—cutting exacerbations and emergency department visits.

Artificial intelligence is emerging as a vital tool for pharmacists in cardiovascular care—supporting clinical decisions, patient education, and adherence while maintaining guideline alignment.

The expanded indication is supported by findings from the phase 3 TRANSCEND clinical trial.

A timely pharmacist referral and collaborative care approach can set off a chain of positive lifestyle changes.